Q-Line Biotech Ltd. is stepping into the primary market with its maiden book-building initial public offering to raise up to Rs. 214.48 crore. Operating in the in-vitro diagnostics sector since 2013, the company develops, manufactures, and markets a diverse range of diagnostic reagents, point-of-care devices, consumables, and laboratory equipment. Its product portfolio covers clinical chemistry, hematology, immunodiagnostics, and molecular diagnostics. Over its twelve-year operating history, the firm has built its infrastructure through in-house research and development, alongside technical collaborations with international partners to ensure its equipment meets strict quality certifications.
The company also adapted its manufacturing lines during the Covid-19 pandemic to produce RT-PCR kits, RNA extraction kits, and viral transport medium kits. As of March 31, 2026, the company employed 19 people in its research and development laboratories out of a total permanent workforce of 362 employees, backed by an additional 223 contract workers.
Structure and Terms of the Public Issue
The offering consists of 6,253,200 equity shares with a face value of Rs. 10 each, fixed at a price band of Rs. 326 to Rs. 343 per share. The issue opens for subscription on May 21, 2026, and closes on May 25, 2026, on the NSE SME Emerge platform. Retail investors must bid for a minimum lot of 800 shares, with subsequent bids in multiples of 400 shares. Based on the upper price band, the total issue size reaches Rs. 214.48 crore, representing 26.81% of the post-issue paid-up capital. The company previously raised Rs. 27.44 crore through a pre-IPO placement of 800,000 shares in May 2026 at Rs. 343 per share.
Proceeds from the fresh issue will primarily support operational growth and debt reduction. The company intends to allocate Rs. 93.50 crore toward working capital requirements and Rs. 90.00 crore for the repayment or prepayment of certain borrowings, with the remaining funds directed toward general corporate needs. Hem Securities Ltd. and Share India Capital Services Pvt. Ltd. are the joint lead managers for the issue, while Purva Sharegistry (India) Pvt. Ltd. serves as the registrar. Hem Finlease Pvt. Ltd. acts as both market maker and syndicate member.
Financial Performance and Valuation Check
The financial track record reveals steady revenue expansion paired with bottom-line volatility. Total income moved from Rs. 184.81 crore in fiscal 2023 to Rs. 206.45 crore in fiscal 2024, and further to Rs. 322.58 crore in fiscal 2025. Net profits tracked at Rs. 32.10 crore, Rs. 34.44 crore, and Rs. 28.13 crore across those same periods. For the nine-month period ended December 31, 2025, the company posted a net profit of Rs. 38.69 crore on a total income of Rs. 236.50 crore. Profitability took a hit in fiscal 2025 due to an extraordinary item of Rs. 16.97 crore, while the surge in earnings during the pre-IPO nine-month window raises sustainability questions.
Balance sheet metrics also warrant close inspection. Total borrowings stood at Rs. 242.57 crore as of December 31, 2025, alongside contingent liabilities of Rs. 61.64 crore. The company reports an average EPS of Rs. 25.00 and an average return on net worth of 23.17% over the last two fiscal years. Net asset value stood at Rs. 140.81 per share as of December 31, 2025, translating to a pre-issue price-to-book value of 2.44 based on the upper price band. Attributing the annualized nine-month fiscal 2026 earnings to the post-IPO fully diluted equity base yields a price-to-earnings ratio of 15.51, which climbs to 28.44 when evaluated against fiscal 2025 results.
Investment Outlook and Key Risks
Because the company operates without direct listed peers in the diagnostics manufacturing space, establishing valuation benchmarks relies entirely on internal numbers. The asking price captures an aggressive valuation that heavily discounts the bumper earnings reported in the run-up to the public issue. While the debt reduction objective addresses a clear balance sheet vulnerability, the heavy reliance on pre-IPO earnings momentum introduces execution risk. Well-informed investors with a high risk tolerance may find Q-Line Biotech IPO pricing, financials, and valuation review a helpful reference when deciding whether to park moderate funds for the long term.
Frequently Asked Questions
The company develops, manufactures, and markets diagnostic reagents, point-of-care devices, consumables, and diagnostic equipment for healthcare providers.
The price band is fixed at Rs. 326 to Rs. 343 per equity share.
The minimum application is for 800 shares, and in multiples of 400 shares thereafter.
The company aims to mobilize up to Rs. 214.48 crore at the upper price band.
The company plans to utilize Rs. 93.50 crore for working capital and Rs. 90.00 crore for the repayment or prepayment of certain borrowings.
The shares will list on the NSE SME Emerge platform.
The issue is jointly lead managed by Hem Securities Ltd. and Share India Capital Services Pvt. Ltd.
